COMPLETE IF KNOWN Application Number 10/659,053 INFORMATION DISCLOSURE FEB 0 9 2004 STATEMENT BY APPLICANT Confirmation Number Filing Date September 8, 2003 Form PTO-1449 (Modified) (Use several sheets if necessary) First Named Inventor James M. LIPTON Group Art Unit Examiner Name 11 of Sheet 1 Attorney Docket No. 54275.8005.US03

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Applicatio Kind C NUMBER (if kno	ode	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
00	A1	09/533,341		Catania Anna P. et al.	03/23/00	
ag	A2	09/957,765		Catania Anna P. et al.	09/21/01	
as	A3	US-2002/0137685		Catania et al.	09/21/01	
W	A4	60/200,287		Lipton, J.M.	04/28/00	
Wa	A5	09/774,282		Lipton, J.M.	01/29/01	
or	A6	09/828,272		Lipton, J.M.	04/06/01	
aro	A7	09/704,327		Lipton, J.M.	11/01/00	
an	A8	5,028,592		Lipton, J.M.	08/05/88	
Od	A9	5,157,023		Lipton, J.M.	03/21/91	
00	A10	US-2002/0146374		Lipton	01/29/01	
w	A11	US-2002/0183255		Lipton et al.	04/06/01	
00	A12	5,739,111		Mahe, Yann	04/29/96	
w	A13	6,001,812		Mahe, Yann	01/23/98	
9	*A14	3,247,182 A		Schwyzer et al.	11/15/61	
OB	*A15	3,300,468 A		Schwyzer et al.	05/13/64	
00	*A16	4,918,055 A		Hruby et al.	02/11/88	
Ġ8	A17	09/535,066		Lipton et al.	03/23/00	
00	A18	10/420,578		Lipton et al.	04/21/03	
00	A19	10/426,647		Lipton et al.	04/29/03	
00	A20	10/298,142		Lipton .	11/15/02	

				FOREIG	SN PATENT DOCUMENTS			
		Fo	reign Patent or A	pplication		Date of Publication or		
Examiner Initial	Cite No.	Office	NUMBER	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	Т
ON	B1		EP 0972 5	22 A1	Mahe et al.	01/19/00		
00	B2		FR 2,784,0)28		04/07/00		

EXAMINER	\bigcap \bigwedge \bigwedge	DATE CONSIDERED
		0/8/02
*EXAMINER:	Initial if reference considered, whether or not criteria is in confor	mance with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication	to application(s).

2

Sheet

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

	. (COMPLETE IF KNOWN	
	Application Number	10/659,053	
į	Confirmation Number		
	Filing Date	September 8, 2003	
	First Named Inventor	James M: LIPTON	
1	Group Art Unit		
	Examiner Name		
	Attorney Docket No.	54275.8005.US03	

07	В3	000	WO 97/10838	Mahe et al.	03/27/97	
\	B4		WO 93/01211	Rathjen et al.	01/21/93	
	B5		PCT/US00/07846		03/23/00	
	B6		WO 99/58101	Jarroussee et al.	11/18/99	
00	B7	1	WO 00/42856	Taylor et al.	07/27/00	

11

EXAMINER

DATE CONSIDERED

6/8/36

• EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

COMPLETE IF KNOWN 10/659,053 INFORMATION DISCLOSURED 0 9 2004 Application Number Confirmation Number STATEMENT BY APPLICANT Filing Date September 8, 2003 Form PTO-1449 (Modified) (Use several sheets if necessary) First Named Inventor James M. LIPTON Group Art Unit **Examiner Name** 3 Sheet of 11 Attomey Docket No. 54275.8005.US03

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т
00 C1		AIRAGHI, L., et al., "Elevated concentrations of plasma α-MSH are associated with reduced disease progression in HIV-infected patients," J. Lab. Clin. Med. 133(3) 309-315 (1999).	
	C2	AIRAGHI L., et al., "Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapy." Am. Heart J. 130: 204-211, (1995).	
	С3	AIRAGHI L., et al., "Plasma concentrations of α-melanocyte-stimulating hormone are elevated in patients on chronic haemodialysis," <i>Nephrology Dialysis</i> Transplantation 15:1212-1216, (2000).	
	C4	ARMSTRONG, "The Microbiology of the Eye." <i>Ophthal. Physiol. Opt.</i> 20: 429-503 (2000).	
	C5	AYLAD et al., "Influence of Oral Acyclovir on Ocular Complications of Herpes zoster ophthalmicus." Eye 8: 70-74 (1994).	
	C6	BAKER, M., et al., "The Relationship between Interleukin-6 and Herpes Simplex Virus Type-1: Implications for Behavior and Immunopathology," <i>Brain Behav. Immun.</i> 13(3):201-11 (1999).	
	C7	BAKER, et al., "Principles of Ambulatory Medicine," Williams and Wilkins (1982).	
	C8	BARCELLINI, W., et al., "Inhibitory Influences of α-MSH peptides on HIV-1 expression in Monocytic cells," 12 th World AIDS Conference Geneva, Abstract No. 60685, June 28-July 3, (1998).	
	C9	BARCELLINI W., et al., "α-MSH peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes," <i>Journal of Leukocyte Biology</i> 68:693-699, (2000).	
	C10	BHATTACHARYA A., et al., "Effect of Cyclic AMP on RNA and Protein Synthesis in Candida albicans," Biochem, Biophysics. Res. Commun., 77: 1438-44 (1977).	
	C11	BICKERS, D., "Sun-Induced Disorders," <i>Emergency Medicine Clinics of North America</i> , 3(4): 659-663, 660 (1985).	
	C12	CAPSONI, F., et al., "Effect of Corticosteriods on Neutrophil Function: Inhibition of Antibody-dependent Cell-Mediated Cytotoxicity (ADCC)," J. Immunopharmacol. 5, 217-30 (1983).	
org	C13	CARTLEDGE, J.D., et al., "Clinically Significant Azole Cross-Resistance in Candida Isolates from HIV-Positive Patients with Oral Candidosis," AIDS 11:1839-44 (1997).	

EXAMINER		DATE CONSIDERED	
	/ shopping	6/8/00	
*EXAMINER:		ce considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conform	ance and not

		·		<u> </u>	<u> </u>	<u>·</u>
٠			OIP	(COMPLETE IF KNOWN	
			()	Application Number	10/659,053	
		I DISCLOSURÉ		Confirmation Number		
		BY APPLICANT	FEB 0 9 2004	Filing Date	September 8, 2003	
	Form PTO-14	149 (Modified) \্র	,	First Named Inventor	James M. LIPTON	,
	(Use several she	ets if necessary	&	Group Art Unit		
			W. OEMan S. C.	Examiner Name		
Sheet	4	of	11	Attorney Docket No.	54275.8005.US03	·

in policy

0	C14	CATANIA, A., et al., "α-Melanocyte Stimulating Hormone in the Modulation of Host Reactions," Endocr. Rev. 14, 564-576 (1993).			
	C15	CATANIA, A., et al., "Melanocortin Peptides Inhibit Production of Proinflammatory Cytokines in Blood of HIV-Infected Patients," Peptides, 19(6): 1099-1104 (1998).			
	C16	CATANIA, A., <i>et al.</i> , "The Neuropeptide α-MSH in HIV Infection and Other Disorders in Humans," <i>Ann. N.Y. Acad. Sci.</i> 840: 848-856 (1998).			
	C17	CATANIA, A., <i>et al.</i> , "The Neuropeptide α-MSH has Specific Receptors on Neutrophils and Reduces Chemotaxis in Vitro," <i>Peptides</i> 17, 675-679 (1996).			
	C18	CATANIA, A., et al., "a-MSH in normal human physiology and disease states," Trends Endocrinol. Metab. 11:304-308, (2000).			
	C19	CATANIA, A., et al., "a-MSH in systemic inflammation: central and peripheral actions," <i>Annals of the New York Academy of Sciences</i> , 885:183-187, (1999).			
	C20	CATANIA, A., et al., "Cytokine antagonists in infectious and inflammatory disorders," Annals of the New York Academy of Sciences 741: 149-161, (1994).			
	C21	CATANIA, A., et al., "α-melanocyte-stimulating hormone peptides in host responses: from basic evidence to human research," Annals of the New York Academy of Sciences 680: 412-423, (1993).			
	C22	CATANIA, A., <i>et al.</i> , "Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients," <i>Crit. Care Med.</i> 28: 1403-1407, (2000).			
	C23	CATANIA, A., et al., "Cytokine antagonists in aged subjects and their relation with cellular immunity," Journal of Gerontology: Biological Sciences 52A: B93-97, (1997).			
	C24	CATANIA, A., et al., "Plasma concentration of cytokine antagonists in patients with HIV infection," Neuroimmunomodulation 1: 42-49, (1994).			
	C25	CATANIA, A., et al., "Proopiomelanocortin-derived peptides and cytokines: relations in patients with acquired immunodeficiency syndrome," Clinical Immunology and Immunopathology 66: 73-79, (1993).			
	C26	CAVELLO, J., et al., "Sunburn", Dermatologic Clinics, 4(2): 181-187, 181 (1986).			
	C27	CERIANI, G., <i>et al.</i> , "Central Neurogenic Antiinflammatory Action of α-MSH: Modulation of Peripheral Inflammation Induced by Cytokines and other Mediators of Inflammation," <i>Neuroendocrinology</i> , 59:138-143 (1994).			
00	C28	CERIANI, G., et al., "The neuropeptide alpha-melanocyte-stimulating hormone inhibits experimental arthritis in rats," <i>Neuroimmunomodulation</i> 1:28-32, (1994).			

EXAMINER	July	DATE CONSIDERED 6/8/06
*EXAMINER:	Initial if reference considered, whether or not criteria is in confor	mance with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication	
[54275-8005/LA04	10360.041	

			OIPA		COMPLETE IF KNOWN	
			4	Application Number	10/659,053	
	INFORMATION	DISCLOSURE	FTO 0 - 3	Confirmation Number		
	STATEMENT E	(2)		Filing Date	September 8, 2003	
	Form PTO-14	l49 (Modified)√		First Named Inventor	James M. LIPTON .	
	(Use several she	ets if necessary	E 75	Group Art Unit		
			UEN	Examiner Name		
Sheet	5	of	11 .	Attorney Docket No.	54275.8005.US03	

Og	C29	CHIAO, H., et al., "α-MSH reduces endotoxin-induced liver inflammation," J. Clin. Invest. 97: 2038-2044, (1996).
	C30	CSATA, M., et al., "Enhancement of Candida albicans killing activity of separated human epidermal cells by alpha-melanocyte stimulating hormone," British Journal of Dermatology, 121(1) 145-147 (1989).
	C31	CUTULI, M., et al., "Antimicrobial effects of α-MSH peptides," Journal of Leukocyte Biology 67:233-239 (2000).
	C32	DEETER, L.B., <i>et al.</i> , "Antipyretic Properties of Centrally Administered α-MSH Fragments in the Rabbit," <i>Peptides</i> 9, 1285-1288 (1989).
	C33	DELGADO, R., et al., "Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia," <i>Journal of Leukocyte Biology</i> , 63: 740-745 (1998).
	C34	DOMK-OPTIZ, I., et al., "Stimulation of Macrophages by Endotoxin Results in the Reactivation of a Persistent Herpes Simplex Virus Infection," Scand J. Immunol. 32(2):69-75 (1990).
	C35	DOUGHTERY et al., "The Role of Tetracycline in Chronic Blepharitis: Inhibition of Lipase Production in Staphylococcus." Inv. Ophthalmol. Vic. Sci. 32: 2970-2975 (1991).
	C36	EBERLE, A., et al., "Hormone-Receptor Interactions, The Message Sequence of α-Melanotropin: Demonstration of Two Active Sites," <i>Clinical Endocrinology</i> 5, Suppl., 41s-48s (1976).
	C37	EBERLE, A.N., "The Melanotrophins," Karger, Basel, Switzerland (1988).
	C38	FAUCHERE, et al., "Potentiation of the antagonistic effect of ACTH ₁₁₋₂₄ on steroidogenesis by synthesis of covalent dimeric conjugates." <i>FEBS</i> 2469, 183(2): 283-286 (1985).
	C39	FAUCHERE, et al., "Synthesis and Antagonistic Activity of Two Covalently Linked Dimers of Adrenocorticotropin-(11-24)-tetradecapeptide." Helvetica Chimica ACTA 68: 770-776 (1985).
	C40	FAUCI, A.S., "Host Factors and the Pathogenesis of HIV-induced Disease," <i>Nature</i> 384: 529 (1996).
o	C41	FEUILLOLEY, et al., Structure-Activity Relationships of Monomeric and Dimeric Synthetic ACTH Fragments in Perifused Frog Adrenal Slices." J. steroid Biochem 35(5): 583-592 (1990).

EXAMINER	(M -	DATE CONSIDERED
	(John St.	6/8/50
*EXAMINER:	Initial if reference considered, whether or not criteria is in confor	mance with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication	to application(s).

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

6

Sheet

OIF			<u> </u>
	4	COMPLETE IF KNOWN	
EB O g	Application Number	10/659,053	
ce u g	Confirmation Number		
•	Filing Date	September 8, 2003	
Manres	First Named Inventor	James M. LIPTON	
VIUEN	Group Art Unit		
	Examiner Name		· · · · · ·
1	Attorney Docket No.	54275.8005.US03	

a	2	C42	FITZPATRICK, et al., "Acute Effects of Ultraviolet Radiation on the Skin: The Sunburn Reaction," Dermatology in General Medicine, 4th Edition, 1651-1655, 1651 (1993).
	,	C43	FITZPATRICK, et al., "Color Atlas and Synopsis of Clinical Dermatology," (1983).
	C44		FOSTER, J., "Sunburn," <i>eMedicine – Online Medical Reference Textbook</i> , (last modified May 1, 2000). http://emedicine.com/emerg/topic798.htm .
	\	C45	FOX, J. A., et.al., "Immunoreactive α-Melanocyte Stimulating Hormone, Its Distribution in the Gastrointestinal Tract of Intact and Hypophysectomized Rats," Life. Sci. 28, 2127-2132 (1981).
		C46	GALIMBERTI, D., et al., "α-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-a by microglial cells activated with β-amyloid and interferon g.," Biochemical Biophysical Research Communications 263: 251-256,(1999).
		C47	GETTING, et al., "POMC Gene-Derived Peptides Activate Melanocortin Type 3 Receptor on Murine Macrophages, Suppress Cytokin Release, and Inhibit Neutrophil Migration in Acute Experimental Inflammation," <i>J. Immunol.</i> , vol. 162, No. 12, pgs. 7446-7453 (1999).
	C	C48	HARRIS, <i>et al.</i> , "Alpha-melanocyte stimulating hormone (α-MSH) and melanin-concentrating hormone (MCH) stimulate phagocytosis by head kidney leucocytes of rainbow trout (Oncorhynchus mykiss) in vitro," <i>Fish & Shell Immunol.</i> , Vol. 8, 8:631-638 (1998).
	C	C49	GOW, N.A., "Germ Tube Growth of Candida albicans," Curr. Topics Med. Myco. 8, 43-55 (1997).
	C	C50	HART, D.A., et al., "Staphylococcus Aureus Strains Differ in Their in Vitro Responsiveness to Human Urokinase: Evidence that Methicillin-Resistant Strains are Predominantly Nonresponsive to the Growth-Enhancing Effects of Urokinase," Can. J. Microbiol. 42: 1024-31 (1966).
	C	C51	"Harry's Comseticology", Chemical Publishing, 7 th ed. (1982).
	C	C52	HILTZ, M. E., <i>et al.</i> , "Anti-inflammatory Activity of a COOH-terminal Fragment of the Neuropeptide α-MSH," <i>FASEB J.</i> 3, 2282-2284 (1989).
	C	C53	HILTZ, M.E., "Anti-inflammatory Activity of α-MSH (11-13) Analogs: Influences of Alterations in Stereochemistry," <i>Peptides</i> 12, 767-71 (1991).
Ce	8 0	C54	HILTZ, M.E., et al., "Alpha-MSH Peptides Inhibit Acute Inflammation and Contact Sensitivity," Peptides, 11:979-982 (1990).

EXAMINER	/) AM	DATE CONSIDERED
	(San J	6/8/04
*EXAMINER:		criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not
	annoideach lackthe cause of this farms with a	

Form PTO-1449 (Modified) (Use several sheets if necessary)

7

Sheet

of

11

<u>.</u>		
	COMPLETE IF KNOWN	 3,00
Application Number	10/659,053	
Confirmation Number		تاريخ
Filing Date	September 8, 2003	
First Named Inventor	James M. LIPTON	
Group Art Unit	· · ·	1
Examiner Name		
Attorney Docket No.	54275.8005.US03	

02	C55	HILTZ, M.E., et al., "α-MSH Peptides Inhibit Acute Inflammation Induced in Mice by rIL-1β, rIL-6, rTNF-α and endogenous pyrogen but not that cause by LTB ₄ , PAF and rIL-8," Cytokine 4(4):320-328 (1992).	
-	C56	HOLDEMAN, M., <i>et al.</i> , "Antipyretic Activity of a Potent α-MSH Analog," <i>Peptides</i> 6, 273-5 (1985).	
	C57	HUANG, et al., "Role of central melanocortins in endotoxin-induced anorexia," Am. J. Physio (Regulatory, Integrative & Comparative Physiology, Vol. 276, No. 3, pgs R864-R871 (1999).	
	C58	HUBERSPITZ et al., "Corneal Ulceration: An Update from a Specialized Ambulatory Care Centre." Klinische. Monals. Augen. 200: 251-256 (1992).	
	C59	HUH S-K., <i>et al.</i> , "The protective effects of α-melanocyte stimulating hormone on canine brain stem ischemia," <i>Neurosurgery</i> 40:132-139, (1997).	
·	C60	ICHIYAMA, T., et al., "Systemically administered a-melanocyte-stimulating hormone peptides inhibit NF-kB activation in experimental brain inflammation," <i>Brain Research</i> 836: 31-37, (1999).	
	C61	ICHIYAMA, T., et al., "α-Melanocyte-stimulating hormone inhibits NF-κB activation and lκBα degradation in human glioma cells and in experimental brain inflammation," <i>Experimental Neurology</i> 157:359-365, (1999).	
	C62	ICHIYAMA, T., et al., "Autocrine a-melanocyte-stimulating hormone inhibits NF-κB activation in human glioma cells," <i>Journal of Neuroscience Research</i> 58:684-689,(1999).	
	C63	ICHIYAMA, T., et al., "NF-kB activation is inhibited in human pulmonary epithelial cells transfected with a-melanocyte-stimulating hormone vector," <i>Peptides</i> 21: 1473-1477, (2000).	
	C64	ICHIYAMA, T., <i>et al.</i> , "Inhibition of peripheral NF-κB activation by central action of α-melanocyte-stimulating hormone," <i>Journal of Neuroimmunology</i> 99: 211-217, (1999).	
	C65	ISHIBASHI & KAUFMAN, "The Effects of Subconjunctival Miconozole in the Treatment of Experimental Candida Keratitis in Rabbits." Arch. Ophthalmol. 103: 1570-1573 (1985).	
	C66	KHURSHID, M.A., et al., "Staphylococcus aureus with Reduced Susceptibility to Vancomycin Illinois, 1999," <i>Morbidity and Mortality Weekly Report</i> , 48(51): 1165-1167 (2000), http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/mm4851a1.htm .	
00	C67	LAZARUS et al., "An in vitro Method Which Assesses Corneal Epithelial Toxicity due to Antineoplastic, Apreservative and Antimicrobial Agents." Lens Eye Toxic. Res. 6: 59-85 (1989).	

EXAMINER	O 44	DATE CONSIDERED	
	June 1	6/8/56	
*EXAMINER:	Initial if reference considered, whether or not criteria is in confor	rmance with MPEP 609. Draw line through citation if not	in conformance and not
	considered Include conv. of this form with next communication		

Ċ

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

11

8

Sheet

	COMPLETE IF KNOWN
Application Number	10/659,053
Confirmation Number	
Filing Date	September 8, 2003
First Named Inventor	James M. LIPTON
Group Art Unit	
Examiner Name	
Attorney Docket No.	54275.8005.US03

ces	C68	LEEMING, "Treatment of Ocular Infections with Topical Antibacterials." <i>Clin. Pharmacokinet.</i> 37: 351-360 (1999).	
	C69	LEIBOWITZ et al., "Human Conjunctivitis: Diagnostic Evaluation." Arch. Ophthalmol. 94: 1747-1749 (1976).	
	C70	LICHTENSTEIGER, W., et al., "Differential Response of Dopamine Neurons to α-Melanotropin and Analogues in Relation to Their Endocrine and Behavioral Potency," <i>Life Sci.</i> 25:2079-2087 (1979).	
	C71	LIPTON, J.M., et.al., "Anti-inflammatory Effects of the Neuropeptide α-MSH in Acute Chronic and Systemic inflammation," Ann. N.Y. Acad. Sci. 741, 137-148 (1994).	
	C72	LIPTON, J.M., et al., "Anti-inflammatory Actions of the Neuroimmunomodulator α-MSH," <i>Immunol. Today</i> 18, 140-145 (1997).	
	C73	LIPTON, J.M., "Neuropeptide α-Melanocyte-Stimulating Hormone in Control of Fever, the Acute Phase Response, and Inflammation," <i>Neuroimmune Networks: Physiology and Diseases</i> , (Alan R. Liss, Inc. 1989) pp. 243-250	
	C74	LIPTON, J.M., "Modulation of Host Defense by the Neuropeptide α-MSH," <i>The Yale Journal of Biology and Medicine</i> 63: 173-182 (1990).	
	C75	LIPTON, J.M., <i>et al.</i> , "Marshaling the anti-inflammatory influence of the neuroimmunomodulator α-MSH," <i>News Physiol. Sci</i> , 15: 192-195, (2000).	
	C76	LIPTON, J.M., et al., "The neuropeptide α-MSH: a modulator of host reactions," Seminars in Clinical Immunology 10: 25-29, (1995).	
	C77	LIPTON, et al., "Mechanisms of antiinflammatory action of the neuro immunomodulatory peptide alpha-MSH," Annals of the N.Y. Acad. Sci., vol. 840, pgs. 373-380 (1998).	
	C78	LOETSCHER, et al., "N-terminal Peptides of Stromal Cell-derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities." <i>J. Biological Chem.</i> 273(35) 22279-22283 (1998).	
	C79	LU & CHAN, "Flavobacterium indologenes Keratitis." Ophthalmologica 211: 98-100 (1997).	
	C80	LUGER, T.A., et al., "Production of Immunosuppressing Melanotropins by Human Keratinocytes," Ann. N.Y. Acad. Sci. 680: 567-570 (1993).	
os	C81	LYSON, K., et al., "Binding of Anti-Inflammatory α-Melanocyte-Stimulating Hormone Peptides and Proinflammatory Cytokines to Receptors on Melanoma Cells," Neuroimmunomodulation, 1:121-126 (1994).	

EXAMINER	/) 1.	DATE CON	SID	ERED	
	(get) *	61	8	100	
*EXAMINER:	Initial if reference considered, whether or not criteria is in confor	mance with M	PEP	609.	Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication				

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

11

9

Sheet

EXAMINER

	COMPLETE IF KNOWN	
Application Number	10/659,053	
Confirmation Number		
Filing Date	September 8, 2003	
First Named Inventor	James M. LIPTON	
Group Art Unit		
Examiner Name		
Attorney Docket No.	54275.8005.US03	

0%	C82	MACALUSO, A., <i>et al.</i> , "Antiinflammatory Influences of α-MSH molecules: Central Neurogenic and Peripheral Actions," <i>The Journal of Neuroscience</i> , 14(4): 2377-2382 (1994).	
	C83	MAYHALL, "Ten Home Remedies for Sunburn," Seasonal Health, (July 14, 2000), http://drkoop.com/wellness/seasonal/summer/sunburn.html .	
	C84	MUGRIDGE, K.G., et al., "α-Melanocyte-Stimulating Hormone reduces interleukin- 1β effects on rat stomach preparations possibly through interference with type I receptor," <i>European Journal of Pharmacology</i> , 197: 151-155 (1991).	
	C85	NOISAKRAN, S., et al., "Lymphocytes Delay Kinetics of HSV-1 Reactivation from in vitro Explants of Latent Infected Trigeminal Ganglia," <i>J. Neuroimmunol.</i> 95(1-2):126-35 (1999).	
	C86	PATEL, A., et al., "Herpes Simplex Virus Type 1 Induction of Persistent NF-κB Nuclear Translocation Increases the Efficiency of Virus Replication," Virology 247(2):212-22 (1998).	
	C87	POTTS, "Sunlight, Sunburn, and Sunscreens," Postgrad. med., 87:52-61 (1990).	
	C88	RAJORA, N., <i>et.al.</i> , "α-MSH Modulates Local and Circulating tumor Necrosis Factor α in Experimental Brain Inflammation," <i>J. Neuroosci</i> , 17, 2181-2186 (1997).	
	C89	RAJORA, N., et al., "α-MSH Production, Receptors, and Influence on Neopterin, in a Human Monocyte/macrophage Cell Line," J. Leukoc. Biol. 59, 248-253 (1996).	
	C90	RAJORA, N., <i>et al.</i> , "α-MSH modulates experimental inflammatory bowel disease," <i>Peptides</i> 18:381-385, (1997).	
	C91	"Remington's Pharmaceutical Sciences," <i>Mack Publishing Co., 18th ed.</i> (1990).	
	C92	RICHARDS, D.B., et al., "Effect of a-MSH (11-13) (Lysine-Proline-Valine) on Fever in the Rabbit," Peptides 5, 815-817 (1984).	
	C93	ROBBINS, S. <i>Pathologic Basis of Disease 5th ed.</i> , Saunders Co., Philadelphia p.335-337, 354-355, 1008, 1037-1038. (1994).	
	C94	RYAN, et al., "Inflammation," a Scope Publication, The Upjohn Company, (1977).	
	C95	SATPATHY & VISHALAKSHI, "Ulcerative Keratitis: Microbial Profile and Sensitivity Pattern: A Five Year Study." <i>Ann. Ophthalmol. Glaucoma</i> 27: 301-306 (1995).	
	C96	STAR, R.A., <i>et al.</i> , "Evidence of Autocrine Modulation of Macrophage Nitric Oxide Synthase by α-MSH," <i>Proc. Nat'l. Acad. Sci. (USA)</i> 92, 8015-8020 (1995).	
08	C97	STEVENS, D.L., "Could Nonsteriodal Anti-inflammatory Drugs (NSAIDs) Enhance Progression of Bacterial Infections to Toxic Shock Syndrome?," Clin. Infect. Dis. 21, 977-80 (1997).	

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

[54275-8005/LA040360.04]

DATE CONSIDERED

.

11

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

10

Sheet

COMPLETE IF KNOWN					
Application Number	10/659,053				
Confirmation Number					
Filing Date	September 8, 2003				
First Named Inventor	James M. LIPTON				
Group Art Unit					
Examiner Name					
Attorney Docket No.	54275.8005.US03				

00	C98	SZALAY, K.S., <i>et al.</i> , "Structure-activity studies with ACTH/α-MSH fragments on corticosteroid secretion of isolated zona glomerulosa and fasciculata cells," <i>Regulatory Peptides</i> , 11: 187-192 (1985).
C99		TAHERZADEH, S., et al., "α-MSH and its receptors in regulation of tumor necrosis factor-a production by human monocyte/macrophages," Am. J. Physiol. 276: R1289-R1294, (1999).
	C100	THODY, A.J., et.al., "MSH Peptides are Present in Mammalian Skin," Peptides 4, 813-815 (1983).
	C101	UEHARA, Y., et al., "Carboxyl-terminal tripeptide of α-Melanocyte-Stimulating Hormone anagonizes interluekin-1-induced anorexia," European Journal of Pharmacology, 220: 119-122 (1992).
	C102	VAN NISPEN, J.W., et al., "Structure-Activity Relationships of Peptides Derived From ACTH, β-LPH and MSH With Regard To Avoidance Behavior in Rats," <i>Pharmac. Ther.</i> 16: 67-102 (1982).
	C103	WALEV, I., et.al., "Enhancement by TNF-alpha of Reactivation and Replication of Latent Herpes Simplex Virus from Trigeminal Ganglia of Mice," Arch Virol. 140(6):987-92 (1995).
	C104	WATANABE, T., et al., "Inhibition of IL-1ß-induced peripheral inflammation by peripheral and central administration of analogs of the neuropeptide α-MSH," Brain Research Bulletin 32: 311-314, (1993).
	C105	WEISS, et al., "Corticotropin-peptide regulation of intracellular cyclic-AMP production in cortical neurons in primary culture," <i>J. Neurochem.</i> Vol. 45, No. 3, pgs 869-874 (1985).
	C106	WENZEL, R.P., et al., "Candida Species: Emerging Hospital Bloodstream Pathogens," Infect. Control. Hosp. Epidemiol. 12: 523-4 (1991).
	C107	WILKINS et al., "Penicillin-Resistant Streptococcus pneumoniae Keratitis." Comea 15: 99-100 (1996).
	C108	WONG, K.Y., et al., "A Potential Mechanism of Local Anti-inflammatory Action of Alpha-Melanocyte-Stimulating Hormone within the Brain: Modulation of Tumor Necrosis Factor-Alpha Production by Human Astrocytic Cells," Neuroimmunomodulation, 4:37-41 (1997).
ay	C109	"Vaginitis," National Institute of Child Health and Human Development - Publications On-line (last modified January 12, 2000). <www.nichd.nih.gov publications="" pubs="" vagtoc.html=""></www.nichd.nih.gov>

EXAMINER A.	DATE CONSIDERED
The state of the s	6/8/02
*EXAMINER: Initial if reference considered, whether or not criteria is in con	ormance with MPEP 609. Draw line through citation if not in conformance and not
considered. Include copy of this form with next communication	n to application(s).
[54275-8005/LA040360.041]	

COMPLETE IF KNOWN INFORMATION DISCLOSURE FEB 0 9 2004 10/659,053 Application Number Confirmation Number STATEMENT BY APPLICANT Filing Date September 8, 2003 Form PTO-1449 (Modified) First Named Inventor James M. LIPTON (Use several sheets if necessary) **Group Art Unit Examiner Name** 11 Sheet 11 of Attorney Docket No. 54275.8005.US03

01	C110	"Tampons and Asbestos, Dioxins, & Toxic Shock Syndrome," FDA Center for Devices and Radiological Health (July 23, 1999), http://www.fda.gov/cdrh/ocd/tamponsabs.html	
oro	C111	"Women's Health, Urinary Tract Infections: A Patient's Guide to Treatment," AMA Health Insight, On-Line Health Information for Everyone (last updated October 30, 1998) http://www.ama-assn.org/insight/h_focus/wom_hlth/uti/uti.htm .	

EXAMINER	\sim			DATE CONSIDERED
1		A	4—	6/8 for
		<u> </u>		

*EXAMINER: Initial of reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE
OF STATEMENT BY APPLICANT
Form PTO-1449 (Modified)
(Use sectoral sheets if necessary)

of

	COMPLETE IF KNOWN	_
Application Number	10/659,053	_
Confirmation Number	3809	_
Filing Date	September 8, 2003	_
First Named Inventor	Anna P. Catania	_
Group Art Unit	1615	_
Examiner Name	Thurman K. Page	
Attorney Docket No.	54275 8005 US03	_

		&/ _		1		Alloniey Docket No.	1 34273.0003.030	<u> </u>	
	Punc	W 0							
Examiner Cite		U.S.	U.S. Patent or Application Kind Code NUMBER (if known)			PATENT DOCUMENTS lame of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages Relevant Figures Appea	
00	B8	6,80	0,291		Liptor	n et al.	10/05/04		
				FC	REIG	N PATENT DOCUMENTS			
Examiner Initials*	Cite No.	For	reign Patent or Ap	Kind	Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
00	B9	wo	87/04623				08/13/87		
Mo	B10	EP	0335662				10/04/89		
	<u> </u>	<u> </u>	OTHER PR	IOR A	RT-NO	ON PATENT LITERATURE D	OCUMENTS		<u></u>
Examiner Initials*	Cite No.	(bo	Include name of	he autho	or (in C/	APITAL LETTERS), title of the article posium, catalog, etc.), date, page(s) and/or country where published.	(when appropriate), title of the item ber(s), publisher, city	т
O	B11	LIPTON, J.M., "The Neuropeptide Alpha-Melanocyte-Stimulating Hormore Inhibits Experimental Arthritis in Rats," <i>Neuroimmunomodulation</i> 1:28-32 (1994).							
									_
				 					
									_
						· · · · · · · · · · · · · · · · · · ·	<u></u>		_
									丅
	<u> </u>								

EXAMINER			DATE CONSIDER	ED
			6/8/03	
*EXAMINER:	Initial if reference co	onsidered, whether or not criteria is in conform	ance with MPEP 609	9. Draw line through citation if not in conformance and not
	considered. Include	copy of this form with next communication t	application(s).	